

Novartis USD 2 mn gene therapy for rare disorder is world's most expensive drug

Novartis has won U.S. approval for its gene therapy Zolgensma for spinal muscular atrophy (SMA), the leading genetic cause of death in infants, and priced the one-time treatment at a record USD 2.125 million.